;PMID: 2106520
;source_file_651.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..170] = [t:45..170]
;2)section:[e:174..261] = [t:174..261]
;3)section:[e:265..382] = [t:265..382]
;4)sentence:[e:386..553] = [t:386..553]
;5)sentence:[e:554..767] = [t:554..767]
;6)sentence:[e:769..1042] = [t:769..1042]
;7)sentence:[e:1043..1199] = [t:1043..1199]
;8)sentence:[e:1200..1393] = [t:1200..1393]
;9)sentence:[e:1395..1578] = [t:1395..1578]
;10)sentence:[e:1579..1791] = [t:1579..1791]
;11)sentence:[e:1792..1913] = [t:1792..1913]
;12)sentence:[e:1914..2392] = [t:1914..2392]
;13)section:[e:2396..2440] = [t:2396..2439]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:2396..2440][t:2396..2439]
;Token/POS Errors
;ERROR_Token in entity file but not tree[2439..2440] ]

;section 0 Span:0..39
;J Biol Chem. 1990 Mar 15;265(8):4541-6.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1990) (NNP:[18..21] Mar) (CD:[22..24] 15)
        (HYPH:[24..29] ;265-LRB-) (CD:[29..30] 8) (JJ:[30..31] -RRB-)
        (CD:[31..36] :4541) (HYPH:[36..37] -) (CD:[37..39] 6.)))

;sentence 1 Span:45..170
;Purification of cholesterol 7 alpha-hydroxylase from human and rat liver and 
;production of inhibiting polyclonal antibodies.
;[61..92]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[148..169]:substance:"polyclonal antibodies"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[45..57] Purification))
      (PP (IN:[58..60] of)
        (NP
          (NP (NN:[61..72] cholesterol) (CD:[73..74] 7) (SYM:[75..80] alpha)
              (HYPH:[80..81] -) (NN:[81..92] hydroxylase))
          (PP (IN:[93..97] from)
            (NP
              (NP (JJ:[98..103] human)
                (NML-1 (-NONE-:[103..103] *P*)))
              (CC:[104..107] and)
              (NP (NN:[108..111] rat)
                (NML-1 (NN:[112..117] liver))))))))
    (CC:[118..121] and)
    (NP
      (NP (NN:[123..133] production))
      (PP (IN:[134..136] of)
        (NP (VBG:[137..147] inhibiting)
           (JJ:[148..158] polyclonal) (NNS:[159..169] antibodies))))
    (.:[169..170] .)))

;section 2 Span:174..261
;Nguyen LB, Shefer S, Salen G, Ness G, Tanaka RD, Packin V, Thomas P, Shore V,
; Batta A.
(SEC
  (FRAG (NNP:[174..180] Nguyen) (NNP:[181..183] LB) (,:[183..184] ,)
        (NNP:[185..191] Shefer) (NNP:[192..194] S,) (NNP:[195..200] Salen)
        (NNP:[201..202] G) (,:[202..203] ,) (NNP:[204..208] Ness)
        (NNP:[209..210] G) (,:[210..211] ,) (NNP:[212..218] Tanaka)
        (NNP:[219..221] RD) (,:[221..222] ,) (NNP:[223..229] Packin)
        (NNP:[230..231] V) (,:[231..232] ,) (NNP:[233..239] Thomas)
        (NNP:[240..241] P) (,:[241..242] ,) (NNP:[243..248] Shore)
        (NNP:[249..250] V) (,:[250..251] ,) (NNP:[253..258] Batta)
        (NN:[259..261] A.)))

;section 3 Span:265..382
;Department of Medicine, University of Medicine and Dentistry of New Jersey,
;New  Jersey Medical School, Newark 07103.
(SEC
  (FRAG (NNP:[265..275] Department) (IN:[276..278] of) (NNP:[279..287] Medicine)
        (,:[287..288] ,) (NNP:[289..299] University) (IN:[300..302] of)
        (NNP:[303..311] Medicine) (CC:[312..315] and) (DT:[316..325] Dentistry)
        (IN:[326..328] of) (NNP:[329..332] New) (NNP:[333..339] Jersey)
        (,:[339..340] ,) (NNP:[341..344] New) (NNP:[346..352] Jersey)
        (NNP:[353..360] Medical) (NNP:[361..367] School) (,:[367..368] ,)
        (NNP:[369..375] Newark) (CD:[376..381] 07103) (.:[381..382] .)))

;sentence 4 Span:386..553
;Cholesterol 7 alpha-hydroxylase, the cytochrome P-450-dependent and 
;rate-controlling enzyme of bile acid synthesis, was purified from rat and
;human  liver microsomes.
;[386..417]:cyp450:"Cholesterol 7 alpha-hydroxylase"
;[423..439]:cyp450:"cytochrome P-450"
;[472..478]:substance:"enzyme"
;[482..491]:substance:"bile acid"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[386..397] Cholesterol) (CD:[398..399] 7) (SYM:[400..405] alpha)
          (HYPH:[405..406] -) (NN:[406..417] hydroxylase))
      (,:[417..418] ,)
      (NP
        (NP (DT:[419..422] the)
          (ADJP
            (ADJP
              (NML (NN:[423..433] cytochrome) (NN:[434..439] P-450))
              (HYPH:[439..440] -) (JJ:[440..449] dependent))
            (CC:[450..453] and)
            (ADJP (NN:[455..459] rate) (HYPH:[459..460] -)
                  (VBG:[460..471] controlling)))
          (NN:[472..478] enzyme))
        (PP (IN:[479..481] of)
          (NP
             (NN:[482..486] bile) (NN:[487..491] acid)
            (NN:[492..501] synthesis)))))
    (,:[501..502] ,)
    (VP (VBD:[503..506] was)
      (VP (VBN:[507..515] purified)
        (NP-2 (-NONE-:[515..515] *))
        (PP (IN:[516..520] from)
          (NP
            (NP (NN:[521..524] rat)
              (NML-1 (-NONE-:[524..524] *P*)))
            (CC:[525..528] and)
            (NP (JJ:[529..534] human)
              (NML-1 (NN:[536..541] liver) (NNS:[542..552] microsomes)))))))
    (.:[552..553] .)))

;sentence 5 Span:554..767
;The purified fractions were assayed in a reconstituted system  containing
;[4-14C]cholesterol, and cholesterol 7 alpha-hydroxylase activities in  these
;fractions increased 500-600-fold relative to whole microsomes.
;[628..646]:substance:"[4-14C]cholesterol"
;[652..683]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[725..737]:quantitative-value:"500-600-fold"
(SENT
  (S
    (S
      (NP-SBJ-1 (DT:[554..557] The) (VBN:[558..566] purified)
                (NNS:[567..576] fractions))
      (VP (VBD:[577..581] were)
        (VP (VBN:[582..589] assayed)
          (NP-1 (-NONE-:[589..589] *))
          (PP (IN:[590..592] in)
            (NP
              (NP (DT:[593..594] a) (VBN:[595..608] reconstituted)
                  (NN:[609..615] system))
              (VP (VBG:[617..627] containing)
                (NP (NN:[628..646] -LSB-4-14C-RSB-cholesterol))))))))
    (,:[646..647] ,) (CC:[648..651] and)
    (S
      (NP-SBJ
        (NP
          (NML (NN:[652..663] cholesterol) (CD:[664..665] 7)
               (SYM:[666..671] alpha) (HYPH:[671..672] -)
               (NN:[672..683] hydroxylase))
          (NNS:[684..694] activities))
        (PP (IN:[695..697] in)
          (NP (DT:[699..704] these) (NNS:[705..714] fractions))))
      (VP (VBD:[715..724] increased)
        (NP-EXT
          (QP (CD:[725..728] 500) (HYPH:[728..729] -) (CD:[729..732] 600)
              (HYPH:[732..733] -) (RB:[733..737] fold)))
        (S-ADV
          (NP-SBJ (-NONE-:[737..737] *))
          (ADJP-PRD (JJ:[738..746] relative)
            (PP (TO:[747..749] to)
              (NP (JJ:[750..755] whole) (NNS:[756..766] microsomes)))))))
    (.:[766..767] .)))

;sentence 6 Span:769..1042
;Polyacrylamide gel electrophoresis of rat microsomes followed by
;immunoblotting  with polyclonal rabbit antisera raised against purified
;cholesterol 7  alpha-hydroxylases revealed two peaks at molecular masses of
;47,000 and 49,000  daltons for both rat and human fractions.
;[769..783]:substance:"Polyacrylamide"
;[855..881]:substance:"polyclonal rabbit antisera"
;[906..939]:cyp450:"cholesterol 7  alpha-hydroxylases"
;[982..988]:quantitative-value:"47,000"
;[993..999]:quantitative-value:"49,000"
;[1001..1008]:quantitative-units:"daltons"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[769..783] Polyacrylamide) (NN:[784..787] gel)
            (NN:[788..803] electrophoresis))
        (PP (IN:[804..806] of)
          (NP (NN:[807..810] rat) (NNS:[811..821] microsomes))))
      (VP (VBN:[822..830] followed)
        (NP (-NONE-:[830..830] *))
        (PP (IN:[831..833] by)
          (NP-LGS
            (NP (NN:[834..848] immunoblotting))
            (PP (IN:[850..854] with)
              (NP
                (NP (JJ:[855..865] polyclonal) (NN:[866..872] rabbit)
                    (NN:[873..881] antisera))
                (VP (VBN:[882..888] raised)
                  (NP (-NONE-:[888..888] *))
                  (PP (IN:[889..896] against)
                    (NP (VBN:[897..905] purified)
                       (NN:[906..917] cholesterol) (CD:[918..919] 7)
                       (SYM:[921..926] alpha) (HYPH:[926..927] -)
                       (NNS:[927..939] hydroxylases))))))))))
    (VP (VBD:[940..948] revealed)
      (NP
        (NP (CD:[949..952] two) (NNS:[953..958] peaks))
        (PP (IN:[959..961] at)
          (NP
            (NP (JJ:[962..971] molecular) (NNS:[972..978] masses))
            (PP (IN:[979..981] of)
              (NP
                (NP (CD:[982..988] 47,000)
                  (NML-2 (-NONE-:[988..988] *P*)))
                (CC:[989..992] and)
                (NP (CD:[993..999] 49,000)
                  (NML-2 (NNS:[1001..1008] daltons))))))))
      (PP (IN:[1009..1012] for)
        (NP (DT:[1013..1017] both)
          (NP (NN:[1018..1021] rat)
            (NML-1 (-NONE-:[1021..1021] *P*)))
          (CC:[1022..1025] and)
          (NP (JJ:[1026..1031] human)
            (NML-1 (NNS:[1032..1041] fractions))))))
    (.:[1041..1042] .)))

;sentence 7 Span:1043..1199
;Increasing amounts of rabbit anti-rat  and anti-human antibodies
;progressively inhibited rat microsomal cholesterol 7  alpha-hydroxylase
;activity up to 80%.
;[1065..1080]...[1097..1107]:substance:"rabbit anti-rat"..."antibodies"
;[1065..1071]...[1086..1107]:substance:"rabbit"..."anti-human antibodies"
;[1147..1179]:cyp450:"cholesterol 7  alpha-hydroxylase"
;[1195..1198]:quantitative-value:"80%"
(SENT
  (S
    (NP-SBJ
      (NP (VBG:[1043..1053] Increasing) (NNS:[1054..1061] amounts))
      (PP (IN:[1062..1064] of)
        (NP
          (NP
            (NML-2 (NN:[1065..1071] rabbit))
            (ADJP (AFX:[1072..1076] anti) (HYPH:[1076..1077] -)
                  (NN:[1077..1080] rat))
            (NML-1 (-NONE-:[1080..1080] *P*)))
          (CC:[1082..1085] and)
          (NP
            (NML-2 (-NONE-:[1085..1085] *P*))
            (ADJP (AFX:[1086..1090] anti) (HYPH:[1090..1091] -)
                  (JJ:[1091..1096] human))
            (NML-1 (NNS:[1097..1107] antibodies))))))
    (ADVP (RB:[1108..1121] progressively))
    (VP (VBD:[1122..1131] inhibited)
      (NP (NN:[1132..1135] rat) (JJ:[1136..1146] microsomal)
        (NML (NN:[1147..1158] cholesterol) (CD:[1159..1160] 7)
             (SYM:[1162..1167] alpha) (HYPH:[1167..1168] -)
             (NN:[1168..1179] hydroxylase))
        (NN:[1180..1188] activity))
      (NP-EXT
        (QP (IN:[1189..1191] up) (TO:[1192..1194] to) (CD:[1195..1197] 80))
        (NN:[1197..1198] %)))
    (.:[1198..1199] .)))

;sentence 8 Span:1200..1393
;In contrast, monospecific antibodies  raised against other purified
;cytochrome P-450 enzymes (P-450f, P-450g, and  P-450j) did not inhibit rat or
;human cholesterol 7 alpha-hydroxylase activity.
;[1213..1236]:substance:"monospecific antibodies"
;[1268..1292]:cyp450:"cytochrome P-450 enzymes"
;[1294..1300]:cyp450:"P-450f"
;[1302..1308]:cyp450:"P-450g"
;[1315..1321]:cyp450:"P-450j"
;[1352..1383]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (PP (IN:[1200..1202] In)
      (NP (NN:[1203..1211] contrast)))
    (,:[1211..1212] ,)
    (NP-SBJ
      (NP (JJ:[1213..1225] monospecific) (NNS:[1226..1236] antibodies))
      (VP (VBN:[1238..1244] raised)
        (NP (-NONE-:[1244..1244] *))
        (PP (IN:[1245..1252] against)
          (NP
            (NP (JJ:[1253..1258] other) (VBD:[1259..1267] purified)
              
              (NML (NN:[1268..1278] cytochrome) (NN:[1279..1284] P-450))
              (NNS:[1285..1292] enzymes))
            (NP (-LRB-:[1293..1294] -LRB-) (NN:[1294..1300] P-450f)
                (,:[1300..1301] ,) (NN:[1302..1308] P-450g) (,:[1308..1309] ,)
                (CC:[1310..1313] and) (NN:[1315..1321] P-450j)
                (-RRB-:[1321..1322] -RRB-))))))
    (VP (VBD:[1323..1326] did) (RB:[1327..1330] not)
      (VP (VB:[1331..1338] inhibit)
        (NP
          (NP (NN:[1339..1342] rat)
            (NML-1 (-NONE-:[1342..1342] *P*)))
          (CC:[1343..1345] or)
          (NP (JJ:[1346..1351] human)
            (NML-1
              (NML (NN:[1352..1363] cholesterol) (CD:[1364..1365] 7)
                   (SYM:[1366..1371] alpha) (HYPH:[1371..1372] -)
                   (NN:[1372..1383] hydroxylase))
              (NN:[1384..1392] activity))))))
    (.:[1392..1393] .)))

;sentence 9 Span:1395..1578
;Immunoblots of rat microsomes with the rabbit anti-rat cholesterol 7 
;alpha-hydroxylase antibody demonstrated that the antibody reacted
;quantitatively  with the rat microsomal enzyme.
;[1434..1491]:substance:"rabbit anti-rat cholesterol 7  alpha-hydroxylase
;antibody"
;[1514..1522]:substance:"antibody"
;[1571..1577]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1395..1406] Immunoblots))
      (PP (IN:[1407..1409] of)
        (NP
          (NP (NN:[1410..1413] rat) (NNS:[1414..1424] microsomes))
          (PP (IN:[1425..1429] with)
            (NP (DT:[1430..1433] the)
               (NN:[1434..1440] rabbit)
              (ADJP (AFX:[1441..1445] anti) (HYPH:[1445..1446] -)
                    (NN:[1446..1449] rat))
              (NML (NN:[1450..1461] cholesterol) (CD:[1462..1463] 7)
                   (SYM:[1465..1470] alpha) (HYPH:[1470..1471] -)
                   (NN:[1471..1482] hydroxylase))
              (NN:[1483..1491] antibody))))))
    (VP (VBD:[1492..1504] demonstrated)
      (SBAR (IN:[1505..1509] that)
        (S
          (NP-SBJ (DT:[1510..1513] the) (NN:[1514..1522] antibody))
          (VP (VBD:[1523..1530] reacted)
            (ADVP (RB:[1531..1545] quantitatively))
            (PP-CLR (IN:[1547..1551] with)
              (NP (DT:[1552..1555] the) (NN:[1556..1559] rat)
                  (JJ:[1560..1570] microsomal) (NN:[1571..1577] enzyme)))))))
    (.:[1577..1578] .)))

;sentence 10 Span:1579..1791
;Microsomes from cholesterol-fed rats showed  increased cholesterol 7
;alpha-hydroxylase mass, whereas treatment with  pravastatin, an inhibitor of
;hydroxy-methylglutaryl-coenzyme A reductase,  reduced enzyme mass.
;[1595..1606]:substance:"cholesterol"
;[1634..1665]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[1696..1707]:substance:"pravastatin"
;[1712..1721]:substance:"inhibitor"
;[1725..1768]:substance:"hydroxy-methylglutaryl-coenzyme A reductase"
;[1779..1785]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1579..1589] Microsomes))
      (PP (IN:[1590..1594] from)
        (NP
          (ADJP (NN:[1595..1606] cholesterol) (HYPH:[1606..1607] -)
                (VBN:[1607..1610] fed))
          (NNS:[1611..1615] rats))))
    (VP (VBD:[1616..1622] showed)
      (NP (VBN:[1624..1633] increased)
        (NML (NN:[1634..1645] cholesterol) (CD:[1646..1647] 7)
             (SYM:[1648..1653] alpha) (HYPH:[1653..1654] -)
             (NN:[1654..1665] hydroxylase))
        (NN:[1666..1670] mass))
      (,:[1670..1671] ,)
      (SBAR-ADV (IN:[1672..1679] whereas)
        (S
          (NP-SBJ
            (NP (NN:[1680..1689] treatment))
            (PP (IN:[1690..1694] with)
              (NP
                (NP (NN:[1696..1707] pravastatin))
                (,:[1707..1708] ,)
                (NP
                  (NP (DT:[1709..1711] an) (NN:[1712..1721] inhibitor))
                  (PP (IN:[1722..1724] of)
                    (NP (NN:[1725..1756] hydroxy-methylglutaryl-coenzyme)
                        (NN:[1757..1758] A) (NN:[1759..1768] reductase)))))))
          (,:[1768..1769] ,)
          (VP (VBD:[1771..1778] reduced)
            (NP (NN:[1779..1785] enzyme) (NN:[1786..1790] mass))))))
    (.:[1790..1791] .)))

;sentence 11 Span:1792..1913
;Microsomes from starved rats contained slightly less  cholesterol 7
;alpha-hydroxylase protein than chow-fed control rats.
;[1846..1885]:cyp450:"cholesterol 7 alpha-hydroxylase protein"
;[1891..1895]:substance:"chow"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1792..1802] Microsomes))
      (PP (IN:[1803..1807] from)
        (NP (VBD:[1808..1815] starved) (NNS:[1816..1820] rats))))
    (VP (VBD:[1821..1830] contained)
      (NP
        (NP
          (ADJP (RB:[1831..1839] slightly) (JJR:[1840..1844] less))
          
          (NML (NN:[1846..1857] cholesterol) (CD:[1858..1859] 7)
               (SYM:[1860..1865] alpha) (HYPH:[1865..1866] -)
               (NN:[1866..1877] hydroxylase))
          (NN:[1878..1885] protein))
        (PP (IN:[1886..1890] than)
          (NP
            (ADJP (NN:[1891..1895] chow) (HYPH:[1895..1896] -)
                  (VBD:[1896..1899] fed))
            (NN:[1900..1907] control) (NNS:[1908..1912] rats)))))
    (.:[1912..1913] .)))

;sentence 12 Span:1914..2392
;These  results indicate a similarity in molecular mass, structure, and
;antigenicity  between rat and human cholesterol 7 alpha-hydroxylases;
;demonstrate the  production of inhibiting anti-cholesterol 7
;alpha-hydroxylase antibodies that  can be used to measure the change in
;cholesterol 7 alpha-hydroxylase enzyme mass  under various conditions; and
;emphasize the unique structure of cholesterol 7  alpha-hydroxylase with
;respect to other cytochrome P-450-dependent hydroxylases.
;[2021..2053]:cyp450:"cholesterol 7 alpha-hydroxylases"
;[2097..2144]:substance:"anti-cholesterol 7 alpha-hydroxylase antibodies"
;[2188..2226]:cyp450:"cholesterol 7 alpha-hydroxylase enzyme"
;[2297..2329]:cyp450:"cholesterol 7  alpha-hydroxylase"
;[2352..2368]:cyp450:"cytochrome P-450"
;[2379..2391]:substance:"hydroxylases"
(SENT
  (S
    (NP-SBJ (DT:[1914..1919] These) (NNS:[1921..1928] results))
    (VP
      (VP (VBP:[1929..1937] indicate)
        (NP
          (NP (DT:[1938..1939] a) (NN:[1940..1950] similarity))
          (PP (IN:[1951..1953] in)
            (NP
              (NP (JJ:[1954..1963] molecular) (NN:[1964..1968] mass))
              (,:[1968..1969] ,)
              (NP (NN:[1970..1979] structure))
              (,:[1979..1980] ,) (CC:[1981..1984] and)
              (NP (NN:[1985..1997] antigenicity))))
          (PP (IN:[1999..2006] between)
            (NP
              (NP (NN:[2007..2010] rat)
                (NML-2 (-NONE-:[2010..2010] *P*)))
              (CC:[2011..2014] and)
              (NP (JJ:[2015..2020] human)
                (NML-2 (NN:[2021..2032] cholesterol) (CD:[2033..2034] 7)
                       (SYM:[2035..2040] alpha) (HYPH:[2040..2041] -)
                       (NNS:[2041..2053] hydroxylases)))))))
      (TO:[2053..2054] ;)
      (VP (VBP:[2055..2066] demonstrate)
        (NP
          (NP (DT:[2067..2070] the) (NN:[2072..2082] production))
          (PP (IN:[2083..2085] of)
            (NP
              (NP (VBG:[2086..2096] inhibiting)
                
                (ADJP (AFX:[2097..2101] anti) (HYPH:[2101..2102] -)
                      (NN:[2102..2113] cholesterol) (CD:[2114..2115] 7)
                      (SYM:[2116..2121] alpha) (HYPH:[2121..2122] -)
                      (NN:[2122..2133] hydroxylase))
                (NNS:[2134..2144] antibodies))
              (SBAR
                (WHNP-1 (WDT:[2145..2149] that))
                (S
                  (NP-SBJ-1 (-NONE-:[2149..2149] *T*))
                  (VP (MD:[2151..2154] can)
                    (VP (VB:[2155..2157] be)
                      (VP (VBN:[2158..2162] used)
                        (NP-1 (-NONE-:[2162..2162] *))
                        (S-PRP
                          (NP-SBJ (-NONE-:[2162..2162] *))
                          (VP (TO:[2163..2165] to)
                            (VP (VB:[2166..2173] measure)
                              (NP
                                (NP (DT:[2174..2177] the)
                                    (NN:[2178..2184] change))
                                (PP (IN:[2185..2187] in)
                                  (NP
                                    
                                    (NML (NN:[2188..2199] cholesterol)
                                         (CD:[2200..2201] 7)
                                         (SYM:[2202..2207] alpha)
                                         (HYPH:[2207..2208] -)
                                         (NN:[2208..2219] hydroxylase))
                                    (NN:[2220..2226] enzyme)
                                    (NN:[2227..2231] mass))))
                              (PP (IN:[2233..2238] under)
                                (NP (JJ:[2239..2246] various)
                                    (NNS:[2247..2257] conditions)))))))))))))))
      (,:[2257..2258] ;) (CC:[2259..2262] and)
      (VP (VBP:[2263..2272] emphasize)
        (NP
          (NP (DT:[2273..2276] the) (JJ:[2277..2283] unique)
              (NN:[2284..2293] structure))
          (PP (IN:[2294..2296] of)
            (NP (NN:[2297..2308] cholesterol) (CD:[2309..2310] 7)
                (SYM:[2312..2317] alpha) (HYPH:[2317..2318] -)
                (NN:[2318..2329] hydroxylase))))
        (PP (IN:[2330..2334] with)
          (NP
            (NP (NN:[2335..2342] respect))
            (PP (TO:[2343..2345] to)
              (NP (JJ:[2346..2351] other)
                (ADJP
                  (NML (JJ:[2352..2362] cytochrome) (NNP:[2363..2368] P-450))
                  (HYPH:[2368..2369] -) (JJ:[2369..2378] dependent))
                (NNS:[2379..2391] hydroxylases)))))))
    (.:[2391..2392] .)))

;section 13 Span:2396..2439
;PMID: 2106520 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2396..2400] PMID) (::[2400..2401] :) (CD:[2402..2409] 2106520)
        (-LRB-:[2410..2411] -LSB-) (NNP:[2411..2417] PubMed)
        (HYPH:[2418..2419] -) (VBN:[2420..2427] indexed) (IN:[2428..2431] for)
        (NNP:[2432..2439] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2439..EOF] ]

(ORPH -RSB-)
